Please login to the form below

Not currently logged in
Email:
Password:

Gregory Gallo joins Treato as chief commercial officer

Brings experience from Quest Diagnostics and Johnson & Johnson

Treato Gregory GalloIsrael-based Treato has appointed Gregory Gallo as its new chief commercial officer.

Working out of the online healthcare consumer insights firm's Princeton, New Jersey office, Gallo will be responsible for leading its business solutions unit as well as expanding the firm's global presence in the pharmaceutical industry.

Ido Hadari, Treato's chief executive officer, said: “Greg has a remarkable track record in helping build, lead and scale innovative businesses.

“We are excited to have Greg join our leadership team and look forward to benefitting from his vast knowledge and commercial experience in the healthcare data and analytics field.”

Gallo has over 20 years of commercial experience in the healthcare and pharmaceutical industries, having held senior roles at IntelliSante, ImpactRX, Johnson & Johnson and Quest Diagnostics.

He joins Treato from Activate Networks, now a part of Decision Resources Group, where he served as chief commercial officer and oversaw its commercial operations and growth.

12th February 2016

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Sciterion

Sciterion is an award winning specialist healthcare communications consultancy within the Havas Health network of companies. We exist to make...

Latest intelligence

World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...
World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...

Infographics